Question 1

What is Regeneron Pharmaceuticals's P/E ratio?

Accepted Answer

Regeneron Pharmaceuticals (REGN) P/E ratio is 15.9× as of July 22, 2026. The ratio is calculated by dividing market capitalisation by trailing twelve-month earnings (net income), using USD-normalised financials (IAS 21 exchange-rate translation for non-USD reporters).

Question 2

How is the P/E ratio calculated?

Accepted Answer

P/E = Share Price ÷ Trailing Twelve-Month (TTM) Diluted EPS, or equivalently Market Capitalisation ÷ TTM Net Income. All inputs are sourced from audited GAAP/IFRS filings and translated to USD using period-end exchange rates so the multiple is comparable across companies and currencies.

Question 3

What is the P/E ratio?

Accepted Answer

The price-to-earnings (P/E) ratio, also called the earnings multiple, measures how much investors pay per dollar of a company's trailing twelve-month (TTM) earnings. It is calculated as share price ÷ TTM diluted EPS (equivalent to market capitalisation ÷ TTM net income). A higher P/E implies the market is pricing in stronger future earnings growth or lower risk; a lower P/E can signal slower expected growth, higher risk, or potential undervaluation.

Question 4

What is a good P/E ratio for Regeneron Pharmaceuticals?

Accepted Answer

There is no universal "good" P/E. As a rule of thumb, the S&P 500 has historically averaged a P/E in the mid-to-high teens; mature, slow-growth businesses commonly trade in the 10–18× range, while high-growth or asset-light companies often trade at 25–50×+. What matters is the comparison to sector peers and to the company's own historical range. For Regeneron Pharmaceuticals specifically, the relevant sector benchmark is the current sector median of 24.2×.

Question 5

Is Regeneron Pharmaceuticals's P/E ratio high or low?

Accepted Answer

Regeneron Pharmaceuticals's P/E ratio of 15.9× is below its own 5-year average of 16.8× and below the sector median of 24.2×. That places the current reading at the 44th percentile of its 10-year history. A higher multiple usually reflects stronger expected growth, lower perceived risk, or higher returns on capital; a lower multiple reflects the opposite.

Question 6

What is Regeneron Pharmaceuticals's historical P/E ratio range?

Accepted Answer

In the available daily series, Regeneron Pharmaceuticals (REGN) P/E ratio has ranged from a low of 7.8× in 2022 to a high of 181.9× in 2004. The 5-year average is 16.8× and the 5-year median is 17.5×.

Question 7

What was Regeneron Pharmaceuticals's P/E ratio in 2025?

Accepted Answer

Regeneron Pharmaceuticals (REGN) P/E ratio at the end of 2025 was 17.6×. Annual values reflect the multiple on the last trading day of each calendar year, using the trailing twelve-month earnings figure available at that date.

Question 8

Why does Regeneron Pharmaceuticals's P/E ratio change over time?

Accepted Answer

Valuation multiples move with two inputs: the numerator (market capitalisation, which tracks the share price) and the denominator (earnings). Share-price changes — driven by interest rates, earnings expectations, risk appetite, and broader market sentiment — typically dominate short-term moves, while changes in the underlying fundamental drive the longer-term trend. As a result, the ratio can rise during stock-price rallies even if the business itself has not become more valuable, and fall during sell-offs even when fundamentals are improving.


2025	$79.4B	$4.5B	17.6×	+0.2×	Dec 31, 2025
2024	$76.9B	$4.41B	17.4×	-6.3×	Dec 31, 2024
2023	$93.6B	$3.95B	23.7×	+5.9×	Dec 31, 2023
2022	$77.2B	$4.34B	17.8×	+9.5×	Dec 31, 2022
2021	$67.1B	$8.08B	8.3×	-6.2×	Dec 31, 2021
2020	$50.9B	$3.51B	14.5×	-5.8×	Dec 31, 2020
2019	$42.9B	$2.12B	20.3×	+2.8×	Dec 31, 2019
2018	$42.9B	$2.44B	17.5×	-18.8×	Dec 31, 2018
2017	$43.6B	$1.2B	36.3×	-12.0×	Dec 31, 2017
2016	$42.5B	$880M	48.3×	-50.3×	Dec 31, 2016
2015	$62.7B	$636M	98.6×	-36.1×	Dec 31, 2015
2014	$46.9B	$348M	134.7×	+49.1×	Dec 31, 2014
2013	$36.3B	$424M	85.6×	+60.4×	Dec 31, 2013
2012	$18.9B	$750M	25.2×	—	Dec 31, 2012
2011	$5.09B	-$222M	—	—	Dec 31, 2011
2010	$2.87B	-$104M	—	—	Dec 31, 2010
2009	$1.94B	-$69.9M	—	—	Dec 31, 2009
2008	$1.45B	-$82.7M	—	—	Dec 31, 2008
2007	$1.9B	-$106M	—	—	Dec 31, 2007
2006	$1.32B	-$102M	—	—	Dec 31, 2006
2005	$892M	-$95.4M	—	—	Dec 31, 2005
2004	$512M	$41.7M	12.3×	—	Dec 31, 2004
2003	$809M	-$106M	—	—	Dec 31, 2003
2002	$817M	-$124M	—	—	Dec 31, 2002


Agilent Technologies (A)	23.1×
Medtronic (MDT)	22.2×
McKesson (MCK)	22.2×
Illumina (ILMN)	21.7×
ResMed (RMD)	21.6×
GE HealthCare (GEHC)	21.6×
Pfizer (PFE)	21.1×
Quest Diagnostics (DGX)	21.1×
Henry Schein (HSIC)	21.0×
AptarGroup (ATR)	20.9×
IQVIA (IQV)	20.7×
Biogen (BIIB)	19.7×
Zoetis (ZTS)	18.9×
Gilead Sciences (GILD)	18.8×
Humana (HUM)	18.5×
Bristol-Myers Squibb (BMY)	17.0×
Elevance Health (ELV)	17.0×
HCA Healthcare (HCA)	15.8×
AstraZeneca (AZN)	14.7×
DaVita (DVA)	13.3×
Incyte (INCY)	13.1×
Cigna (CI)	11.1×
Novo Nordisk (NVO)	8.6×
Solventum (SOLV)	7.9×
Universal Health Services (UHS)	7.2×

P/E Ratio for Regeneron Pharmaceuticals (REGN) 2004-2026

P/E Ratio daily chart for Regeneron Pharmaceuticals (REGN)

Historical P/E Ratio for Regeneron Pharmaceuticals (REGN) from 2002 to 2025

About P/E Ratio at Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals P/E Ratio by Year

Regeneron Pharmaceuticals P/E Ratio 2025: 17.6×

Regeneron Pharmaceuticals P/E Ratio 2024: 17.4×

Regeneron Pharmaceuticals P/E Ratio 2023: 23.7×

Regeneron Pharmaceuticals P/E Ratio 2022: 17.8×

Regeneron Pharmaceuticals P/E Ratio 2021: 8.3×

Sector peers by P/E Ratio — chart

Sector peers by P/E Ratio — table

Frequently asked questions

Regeneron Pharmaceuticals (REGN) Key Financials